RGEN
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Financial indicators Supports a bullish reading. Current ratio 8.37 · operating margin 8.1%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
VENTE TOTALE: 18 429 titres (~3 319 846,50 $ US)
- Insiders
- Loeillot Olivier
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$3,319,846
Avg sell (VWAP, 90d window) $175.93 vs last close $189.68 (+7.8%)
- Last activity
- 2026-09-24
- Liquidity
- Liquid $195,403,272/day · 20d vol
- Last synced
-
2026-09-25 21:10:51
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-21 | Loeillot Olivier | Sell | 5,426 | $180.00 | $976,680 | Form 4 |
| 2026-09-04 | Loeillot Olivier | Sell | 3,035 | $165.90 | $503,506 | Form 4 |
| 2026-08-20 | Loeillot Olivier | Sell | 5,426 | $180.00 | $976,680 | Form 4 |
| 2026-07-16 | Garland Jason K | Sell | 530 | $150.00 | $79,500 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-25
RGEN combines strong liquidity (90) with weak fundamentals (45) and an absent catalyst signal (25), yielding a low composite score that does not support a tactical entry.
The first sentence of the analysis written for RGEN on 2026-09-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 47.1% | 43.3% | 44.0% | 56.9% | 58.3% | |
| Ebit Margin | 11.6% | -1.0% | 9.4% | 27.5% | 24.6% | |
| Ebitda Margin | 22.3% | 12.7% | 23.0% | 34.6% | 30.3% | |
| Operating Profit Margin | 8.1% | -5.5% | 7.5% | 28.0% | 24.9% | |
| Pretax Profit Margin | 8.5% | -4.3% | 9.0% | 27.3% | 22.9% | |
| Continuous Operations Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Net Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Bottom Line Profit Margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | |
| Current Ratio | 8.374 | 8.408 | 6.738 | 2.469 | 2.483 | |
| Quick Ratio | 7.119 | 7.281 | 5.511 | 1.880 | 1.991 | |
| Solvency Ratio | 0.151 | 0.071 | 0.140 | 0.391 | 0.274 | |
| Cash Ratio | 4.167 | 5.973 | 4.555 | 1.295 | 1.609 | |
| Price To Earnings Ratio | 188.345 | -312.913 | 280.938 | 50.540 | 113.665 | |
| Price To Earnings Growth Ratio | -0.651 | 1.821 | -3.473 | 1.154 | 1.089 | |
| Forward Price To Earnings Growth Ratio | -0.651 | 1.821 | -3.473 | 1.154 | 1.089 | |
| Price To Earnings Diluted Ratio | 190.535 | -312.913 | 285.397 | 52.256 | 118.232 | |
| Price To Earnings Diluted Growth Ratio | -0.664 | 1.809 | -3.543 | 1.171 | 1.161 | |
| Price To Book Ratio | 4.375 | 4.081 | 5.099 | 4.914 | 8.325 | |
| Price To Sales Ratio | 12.481 | 12.691 | 15.843 | 11.715 | 21.729 | |
| Price To Free Cash Flow Ratio | 98.133 | 56.507 | 133.704 | 242.402 | 280.590 | |
| Price To Operating Cash Flow Ratio | 78.477 | 45.906 | 87.944 | 54.566 | 122.422 | |
| Debt To Assets Ratio | 0.234 | 0.243 | 0.251 | 0.167 | 0.155 | |
| Debt To Equity Ratio | 0.328 | 0.348 | 0.362 | 0.221 | 0.209 | |
| Debt To Capital Ratio | 0.247 | 0.258 | 0.266 | 0.181 | 0.173 | |
| Long Term Debt To Capital Ratio | 0.205 | 0.210 | 0.206 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.401 | 1.434 | 1.441 | 1.325 | 1.348 | |
| Working Capital Turnover Ratio | 0.761 | 0.673 | 0.821 | 1.394 | 1.177 | |
| Operating Cash Flow Ratio | 0.864 | 1.383 | 0.691 | 0.426 | 0.317 | |
| Operating Cash Flow Sales Ratio | 0.159 | 0.276 | 0.180 | 0.215 | 0.177 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.800 | 0.812 | 0.658 | 0.225 | 0.436 | |
| Debt Service Coverage Ratio | 3.371 | 3.623 | 1.563 | 0.849 | 0.664 | |
| Interest Coverage Ratio | 2.571 | -1.556 | 4.758 | 75.469 | 13.155 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.446 | 0.000 | 1.640 | 0.605 | 0.466 | |
| Operating Cash Flow Coverage Ratio | 0.170 | 0.256 | 0.160 | 0.407 | 0.325 | |
| Capital Expenditure Coverage Ratio | 4.992 | 5.330 | 2.922 | 1.290 | 1.774 | |
| Dividend Paid And Capex Coverage Ratio | 4.992 | 5.330 | 2.922 | 1.290 | 1.774 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 56.837 | 99.435 | 68.667 | 33.498 | 70.510 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 47.1% | ▲3.8% | ▼-2.8% |
| Ebit Margin | 11.6% | ▲12.6% | ▼-2.8% |
| Ebitda Margin | 22.3% | ▲9.6% | ▼-2.3% |
| Operating Profit Margin | 8.1% | ▲13.6% | ▼-4.5% |
| Pretax Profit Margin | 8.5% | ▲12.7% | ▼-4.2% |
| Continuous Operations Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Net Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Bottom Line Profit Margin | 6.6% | ▲10.6% | ▼-3.5% |
| Current Ratio | 8.374 | ▼-0.034 | ▲2.679 |
| Quick Ratio | 7.119 | ▼-0.162 | ▲2.363 |
| Solvency Ratio | 0.151 | ▲0.080 | ▼-0.054 |
| Cash Ratio | 4.167 | ▼-1.806 | ▲0.647 |
| Price To Earnings Ratio | 188.345 | ▲501.258 | ▲124.230 |
| Price To Earnings Growth Ratio | -0.651 | ▼-2.472 | ▼-0.639 |
| Forward Price To Earnings Growth Ratio | -0.651 | ▼-2.472 | ▼-0.639 |
| Price To Earnings Diluted Ratio | 190.535 | ▲503.448 | ▲123.834 |
| Price To Earnings Diluted Growth Ratio | -0.664 | ▼-2.473 | ▼-0.651 |
| Price To Book Ratio | 4.375 | ▲0.294 | ▼-0.984 |
| Price To Sales Ratio | 12.481 | ▼-0.209 | ▼-2.410 |
| Price To Free Cash Flow Ratio | 98.133 | ▲41.627 | ▼-64.134 |
| Price To Operating Cash Flow Ratio | 78.477 | ▲32.571 | ▲0.614 |
| Debt To Assets Ratio | 0.234 | ▼-0.009 | ▲0.024 |
| Debt To Equity Ratio | 0.328 | ▼-0.020 | ▲0.034 |
| Debt To Capital Ratio | 0.247 | ▼-0.011 | ▲0.022 |
| Long Term Debt To Capital Ratio | 0.205 | ▼-0.006 | ▲0.081 |
| Financial Leverage Ratio | 1.401 | ▼-0.034 | ▲0.011 |
| Working Capital Turnover Ratio | 0.761 | ▲0.088 | ▼-0.204 |
| Operating Cash Flow Ratio | 0.865 | ▼-0.519 | ▲0.128 |
| Operating Cash Flow Sales Ratio | 0.159 | ▼-0.117 | ▼-0.043 |
| Free Cash Flow Operating Cash Flow Ratio | 0.800 | ▼-0.013 | ▲0.213 |
| Debt Service Coverage Ratio | 3.372 | ▼-0.251 | ▲1.357 |
| Interest Coverage Ratio | 2.571 | ▲4.127 | ▼-16.308 |
| Short Term Operating Cash Flow Coverage Ratio | 5.446 | ▲5.446 | ▲3.815 |
| Operating Cash Flow Coverage Ratio | 0.170 | ▼-0.085 | ▼-0.093 |
| Capital Expenditure Coverage Ratio | 4.992 | ▼-0.338 | ▲1.731 |
| Dividend Paid And Capex Coverage Ratio | 4.992 | ▼-0.338 | ▲1.731 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 56.837 | ▼-42.598 | ▼-8.952 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $9.21B | $8.05B | $10.02B | $9.39B | $14.57B | |
| Enterprise value | $9.34B | $7.98B | $9.98B | $9.29B | $14.33B | |
| EV / Sales | 12.65x | 12.58x | 15.78x | 11.59x | 21.38x | |
| EV / Op. cash flow | 79.53x | 45.50x | 87.60x | 53.98x | 120.42x | |
| EV / Free cash flow | 99.45x | 56.01x | 133.18x | 239.81x | 276.01x | |
| EV / EBITDA | 56.84x | 99.44x | 68.67x | 33.50x | 70.51x | |
| Net debt / EBITDA | 0.75x | -0.89x | -0.27x | -0.36x | -1.17x | |
| Current ratio | 8.37x | 8.41x | 6.74x | 2.47x | 2.48x | |
| Income quality | 2.40x | -6.87x | 2.74x | 0.93x | 0.93x | |
| Graham number | $27 | — | $23 | $51 | $41 | |
| Graham net-net | $2 | $1 | $1 | $4 | $3 | |
| Tax burden | 78.4% | 94.4% | 62.8% | 84.9% | 83.6% | |
| Interest burden | 72.9% | 428.9% | 95.8% | 99.5% | 93.2% | |
| Working capital | $1.00B | $939.3M | $946.4M | $593.9M | $556.4M | |
| Invested capital | $2.81B | $2.70B | $2.66B | $2.13B | $1.98B | |
| Return on assets | 1.7% | -0.9% | 1.3% | 7.3% | 5.4% | |
| Operating ROA | 2.1% | -1.2% | 1.8% | 9.2% | 7.8% | |
| Return on tangible assets | 3.4% | -1.8% | 2.5% | 14.1% | 11.1% | |
| Return on equity | 2.3% | -1.3% | 1.8% | 9.7% | 7.3% | |
| Return on invested capital | 1.6% | -1.2% | 1.1% | 7.9% | 6.2% | |
| Return on capital employed | 2.1% | -1.3% | 1.8% | 10.6% | 8.4% | |
| Earnings yield | 0.5% | -0.3% | 0.4% | 2.0% | 0.9% | |
| Free cash flow yield | 1.0% | 1.8% | 0.7% | 0.4% | 0.4% | |
| Capex / Op. cash flow | 20.0% | 18.8% | 34.2% | 77.5% | 56.4% | |
| Capex / Depreciation | 24.3% | 38.0% | 57.3% | 233.9% | 174.5% | |
| Capex / Sales | 3.2% | 5.2% | 6.2% | 16.6% | 10.0% | |
| SG&A / Sales | 39.4% | 41.5% | 34.6% | 26.9% | 27.4% | |
| R&D / Sales | 7.3% | 6.8% | 6.8% | 5.5% | 5.1% | |
| Stock comp / Sales | 4.4% | 7.6% | 4.0% | 3.4% | 4.1% | |
| Intangibles / Total assets | 50.9% | 50.5% | 49.2% | 48.0% | 50.8% | |
| Days sales outstanding | 78d | 77d | 72d | 53d | 64d | |
| Days payables outstanding | 28d | 33d | 20d | 29d | 47d | |
| Operating cycle | 238d | 222d | 280d | 304d | 305d | |
| Cash conversion cycle | 210d | 190d | 260d | 275d | 258d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+14.4%EV / Sales ▲+0.6%EV / EBITDA ▼-42.8%EV / Op. cash flow ▲+34.032Earnings yield ▲+0.008
Profitability
Return on equity ▲+0.036Return on assets ▲+0.026Return on invested capital ▲+0.029Return on capital employed ▲+0.034Operating ROA ▲+0.033Income quality ▲+9.276Tax burden ▼-0.160
Efficiency
Days sales outstanding ▲+1.249Days payables outstanding ▼-4.558Operating cycle ▲+15.489Cash conversion cycle ▲+20.047Capex / Sales ▼-0.020R&D / Sales ▲+0.005
Balance-sheet strength
Current ratio ▼-0.034Net debt / EBITDA ▲+1.640Working capital ▲+62305000.000Invested capital ▲+107004000.000Intangibles / Total assets ▲+0.004
Change over 5 years
Valuation
Market cap ▼-36.8%EV / Sales ▼-40.8%EV / EBITDA ▼-19.4%EV / Op. cash flow ▼-40.892Earnings yield ▼-0.003Graham number ▼-13.786
Profitability
Return on equity ▼-0.050Return on assets ▼-0.038Return on invested capital ▼-0.046Return on capital employed ▼-0.063Operating ROA ▼-0.058Income quality ▲+1.474Tax burden ▼-0.052
Efficiency
Days sales outstanding ▲+14.490Days payables outstanding ▼-19.274Operating cycle ▼-67.358Cash conversion cycle ▼-48.084Capex / Sales ▼-0.068R&D / Sales ▲+0.022
Balance-sheet strength
Current ratio ▲+5.891Net debt / EBITDA ▲+1.924Working capital ▲+445144000.000Invested capital ▲+827692000.000Intangibles / Total assets ▲+0.001
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-04-07 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-25 Repligen (NASDAQ:RGEN) Hits New 52-Week High – Still a Buy? Repligen Corporation (NASDAQ: RGEN - Get Free Report) reached a new 52-week high on Wednesday. The stock traded as high as $188.95 and last traded at $186.9330, with a volume of 25119 shares traded. The stock had previously closed at $186.75. Wall Street Analysts Forecast Growth A number of brokerages have issued reports on RGEN. HSBC
- 2026-09-19 Tidal Investments LLC Raises Holdings in Repligen Corporation $RGEN Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,863 shares of the biotechnology company''s stock after acquiring an additional 3,803 shares during
- 2026-09-10 BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t.
- 2026-09-09 Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- 2026-08-27 Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report? Repligen (RGEN) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-27 Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
- 2026-08-27 American Capital Management Inc. Makes New $49.26 Million Investment in Repligen Corporation $RGEN American Capital Management Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 361,055 shares of the biotechnology company''s stock, valued at approximately $49,262,000. Repligen comprises
- 2026-08-26 5 Biotech Stocks Worth Adding to Your Portfolio Now New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
- 2026-08-26 Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET.
- 2026-08-26 25,992 Shares in Repligen Corporation $RGEN Acquired by Bank of Nova Scotia Bank of Nova Scotia acquired a new stake in Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,992 shares of the biotechnology company''s stock, valued at approximately $3,547,000. Several other institutional investors have also modified their holdings